ZUG, Switzerland, March 20, 2025 (GLOBE NEWSWIRE) -- The attached notifications relate to trades entered into by a PDMR of the Company pursuant to a 10b5-1 trading plan, in accordance with Rule 10b5-1(c)(1) of the Securities Exchange Act of 1934, as amended.
See more here:
Oculis Publishes Notifications of Transactions by Person Discharging Managerial Responsibilities
AURORA, Colo., March 21, 2025 (GLOBE NEWSWIRE) -- NeuroQuiet is intricately designed to promote optimal ear health and support auditory functions and overall ear wellness. Its formula enhances brain performance and focuses on improving memory, clarity, and mental sharpness.
See the original post:
NeuroQuiet Reviews (Is It Safe And Legit to Use?) Tinnitus Relief Ingredients, Side Effects, And Benefits!
BOSTON and SAN DIEGO, March 21, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced two encore poster presentations at the 2025 American Academy of Neurology (AAN) Annual Meeting, taking place from April 5 to April 9, 2025, in San Diego, California. The data from these posters was originally presented at the American Epilepsy Society (AES) Annual Meeting in December 2024.
Go here to read the rest:
Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting
MELBOURNE, Australia and INDIANAPOLIS, March 21, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United States (U.S.) Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Gozellix® (TLX007-CDx, kit for the preparation of gallium-68 (68Ga) gozetotide injection), Telix’s next-generation PSMA-PET imaging1 agent for prostate cancer.
See original here:
FDA Approves New Prostate Cancer Imaging Agent Gozellix®
— First and only EZH2 inhibitor approved by the NMPA —
New Drug Application (NDA) for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma Under Review with Prescription Drug User Fee Act (PDUFA) Action Date of August 18, 2025
Excerpt from:
Chimerix Reports Fourth Quarter and Year End 2024 Financial Results
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS21 March 2025 at 15.00 EET
View original post here:
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
PALO ALTO, Calif., March 21, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases, today announced that on March 19, 2025, the compensation committee of BridgeBio’s board of directors approved equity grants to 10 new employees in restricted stock units for an aggregate of 30,782 shares of the Company’s common stock. One-fourth of the shares underlying each employee’s restricted stock units will vest on February 16, 2026, with one-twelfth of the remaining shares underlying each such employee’s restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee’s continued employment with the Company or one of its subsidiaries on such vesting dates. All of the above-described awards were made under BridgeBio’s Amended and Restated 2019 Inducement Equity Plan (the “Plan”).
Go here to read the rest:
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SAN CARLOS, Calif., March 21, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on March 20, 2025 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 308,710 shares of Iovance’s common stock to forty-three new, non-executive employees.
More:
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)